Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Aug 2;5:e15691. doi: 10.7554/eLife.15691

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016, Chao et al

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

PMC Copyright notice

Figure 4. — Twenty patients were randomly assigned to treatment of cTACE or TILA-TACE. (A) Tumor response rate to cTACE and representative MRI images of tumor before and after treatment. 10 patients were treated with cTACE. (B) Tumor response rate to TILA-TACE and representative MRI image of tumor before and after treatment. 10 patients were treated with TILA-TACE. (C) The pattern of tumor response to TILA-TACE and cTACE. The difference between 2 groups was statistically significant (p=0.003), as assessed using proportional odds model. CR, complete necrosis; PR, viable tumor volume less than 50% of the viable tumor volume before treatment; SD, viable tumor volume larger than 50% of the viable tumor volume before treatment; PD, viable tumor volume larger than 100% after treatment.

Figure 4—source data 1. The criteria and classification of response to treatment in the randomized study after the first round treatment.

elife-15691-fig4-data1.xlsx^{(11.8KB, xlsx)}